Skip to main content
Premium Trial:

Request an Annual Quote

Somalogic Collaborating With Janssen on Protein Biomarker Research

NEW YORK (GenomeWeb) – Somalogic said today it has entered a collaboration with Janssen Research & Development to analyze clinical samples using its SomaScan proteomics platform.

Under the agreement, Somalogic will measure roughly 5,000 proteins in at least 15,000 clinical samples to discover and validate protein markers to help predict, diagnose, monitor, and treat disease including rheumatoid arthritis, inflammatory bowel disease, lupus, and cardiovascular and metabolic conditions.

The deal is part of Boulder, Colorado-based Somalogic's recent move from offering its SomaScan platform on a fee-for-service basis to a collaboration-based model in which it retains access to the data generated by its work with outside parties. In December the company announced a collaboration with DeCode Genetics to characterize 40,000 of that firm's patient samples.

"We are happy that the Janssen research teams are exploring the potential of our protein-measurement platform for their drug discovery and development efforts," Roy Smythe, Somalogic's CEO, said in a statement. "We prefer this kind of ‘win-win’ collaboration, where each party shares data and expertise with the other in an effort to achieve the high value goal of more rapidly advancing healthcare."

Financial and other terms of the agreement were not disclosed.